Synthesis and biological evaluation of lycorine derivatives as dual inhibitors of human acetylcholinesterase and butyrylcholinesterase

Chemistry Central Journal

Volumn 6, Issue 1, 2012, Pages

  Wang, Yue Hu ^a   Wan, Qin Li ^a   Gu, Cheng Ding ^b   Luo, Huai Rong ^a   Long, Chun Lin ^a,c  

^a KUNMING INSTITUTE OF BOTANY   (China)

^b NANJING UNIVERSITY   (China)

^c MINZU UNIVERSITY OF CHINA   (China)

Author keywords

Acetylcholinesterase; Amaryllidaceae alkaloids; Butyrylcholinesterase; Lycorine

Indexed keywords

EID: 84865831126     PISSN: None     EISSN: 1752153X     Source Type: Journal    
DOI: 10.1186/1752-153X-6-96     Document Type: Article

References (19)

1. Cisse M, Mucke L. Alzheimer's disease: A prion protein connection. Nature 2009, 457:1090-1091. 10.1038/4571090a, 19242462.
2. Leifer BP. Early diagnosis of Alzheimer's disease: clinical and economic benefits. J Am Geriatr Soc 2003, 51:S281-S288. 10.1046/j.1532-5415.5153.x, 12801384.
3. Mohamed T, Rao PPN. Alzheimers disease: emerging trends in small molecule therapies. Curr Med Chem 2011, 18:4299-4320. 10.2174/092986711797200435, 21861820.
4. Walsh R, Rockwood K, Martin E, Darvesh S. Synergistic inhibition of butyrylcholinesterase by galantamine and citalopram. Biochim Biophys Acta 2011, 1810:1230-1235. 10.1016/j.bbagen.2011.08.010, 21872646.
5. Greig NH, Utsuki T, Ingram DK, Wang Y, Pepeu G, Scali C, Yu QS, Mamczarz J, Holloway HW, Giordano T. Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer β-amyloid peptide in rodent. Proc Natl Acad Sci USA 2005, 102:17213-17218. 10.1073/pnas.0508575102, 1288010, 16275899.
6. Furukawa-Hibi Y, Alkam T, Nitta A, Matsuyama A, Mizoguchi H, Suzuki K, Moussaoui S, Yu QS, Greig NH, Nagai T. Butyrylcholinesterase inhibitors ameliorate cognitive dysfunction induced by amyloid-[beta] peptide in mice. Behav Brain Res 2011, 1:222-229.
7. Darvesh S, Cash MK, Reid GA, Martin E, Mitnitski A, Geula C. Butyrylcholinesterase is associated with β-amyloid plaques in the transgenic APPSWE/PSEN1dE9 mouse model of Alzheimer disease. J Neuropathol Exp Neurol 2012, 71:2-14. 10.1097/NEN.0b013e31823cc7a6, 22157615.
8. Elgorashi EE, Stafford GI, van Staden J. Acetylcholinesterase enzyme inhibitory effects of Amaryllidaceae alkaloids. Planta Med 2004, 70:260-262.
9. McNulty J, Nair JJ, Little JRL, Brennan JD, Bastida J. Structure-activity studies on acetylcholinesterase inhibition in the lycorine series of Amaryllidaceae alkaloids. Bioorg Med Chem Lett 2010, 20:5290-5294. 10.1016/j.bmcl.2010.06.130, 20655219.
10. Wang YH, Zhang ZK, Yang FM, Sun QY, He HP, Di YT, Mu SZ, Lu Y, Chang Y, Zheng QT, Ding M, Dong JH, Hao XJ. Benzylphenethylamine alkaloids from Hosta plantaginea with inhibitory activity against tobacco mosaic virus and acetylcholinesterase. J Nat Prod 2007, 70:1458-1461. 10.1021/np0702077, 17822295.
11. Wang YH, Gao S, Yang FM, Sun QY, Wang JS, Liu HY, Li CS, Di YT, Li SL, He HP, Hao XJ. Structure elucidation and biomimetic synthesis of hostasinine A, a new benzylphenethylamine alkaloid from Hosta plantaginea. Org Lett 2007, 9:5279-5281. 10.1021/ol702438h, 17994756.
12. Wang H, Wang YH, Zhao FW, Huang QQ, Xu JJ, Ma LJ, Long CL. Benzylphenethylamine alkaloids from the bulbs and flowers of Lycoris radiata. Chin Herb Med 2011, 3:60-63.
13. Elgorashi E, Malan S, Stafford G, Van Staden J. Quantitative structure-activity relationship studies on acetylcholinesterase enzyme inhibitory effects of Amaryllidaceae alkaloids. S Afr J Bot 2006, 72:224-231.
14. Ellman GL, Courtney KD, Andres V, Featherstone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961, 7:88-95. 10.1016/0006-2952(61)90145-9, 13726518.
15. Christensen SM, Hansen HF, Koch T. Molar-scale synthesis of 1, 2: 5, 6-di-O-isopropylidene-α-D-allofuranose: DMSO oxidation of 1, 2: 5, 6-di-O-isopropylidene-α-D-glucofuranose and subsequent sodium borohydride reduction. Org Process Res Dev 2004, 8:777-780.
16. Cavalli A, Bolognesi ML, Minarini A, Rosini M, Tumiatti V, Recanatini M, Melchiorre C. Multi-target-directed ligands to combat neurodegenerative diseases. J Med Chem 2008, 51:347-372. 10.1021/jm7009364, 18181565.
17. Evdokimov NM, Lamoral-Theys D, Mathieu V, Andolfi A, Frolova LV, Pelly SC, van Otterlo WAL, Magedov IV, Kiss R, Evidente A, Kornienko A. In search of a cytostatic agent derived from the alkaloid lycorine: Synthesis and growth inhibitory properties of lycorine derivatives. Bioorg Med Chem 2011, 19:7252-7261. 10.1016/j.bmc.2011.09.051, 22019045.
18. Lamoral-Theys D, Andolfi A, Van Goietsenoven G, Cimmino A, Le Calvé B, Wauthoz N, Mégalizzi V, Gras T, Bruyére C, Dubois J, Mathieu V, Kornienko A, Kiss R, Evidente A. Lycorine, the main phenanthridine Amaryllidaceae alkaloid, exhibits significant antitumor activity in cancer cells that display resistance to proapoptotic stimuli: an investigation of structure-activity relationship and mechanistic insight. J Med Chem 2009, 52:6244-6256. 10.1021/jm901031h, 3205972, 19788245.
19. Cedron JC, Gutierrez D, Flores N, Ravelo AG, Estevez-Braun A. Synthesis and antiplasmodial activity of lycorine derivatives. Bioorg Med Chem 2010, 18:4694-4701. 10.1016/j.bmc.2010.05.023, 20627737.